New drug MRG007 enters early human testing for Hard-to-Treat cancers

NCT ID NCT07066657

Recruiting now Disease control Sponsor: ArriVent BioPharma, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a new drug called MRG007 (ARR-217) in people with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check if the drug can shrink tumors. About 405 participants with colorectal, gastric, or pancreatic cancer will take part across multiple centers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

MRG007 (ARR-217)

What this could lead to

If it works, this could point toward a new treatment option for people with advanced solid tumors like colorectal, gastric, or pancreatic cancer.

What could go wrong

This is a very early Phase 1 trial, so the main goal is safety, not effectiveness. The drug may not shrink tumors or could cause serious side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm gastric cancer gastric neoplasm malignant pancreatic neoplasm metastatic malignant neoplasm pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER GASTRIC CANCER LOCALLY ADVANCED OR METASTATIC SOLID TUMORS PANCREATIC CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

Army Medical Center of PLA
RECRUITING

Chongqing, Chongqing Municipality, 400000, China
Beijing Gobroad Hospital
RECRUITING

Beijing, Beijing Municipality, 102200, China
Cancer Hospital of Shandong First Medical University
RECRUITING

Shandong, Jinan, 250000, China
Fred Hutchinson Cancer Center
RECRUITING

Seattle, Washington, 98109, United States
Harbin Medical University Cancer Hospital
RECRUITING

Heilongjiang, Harbin, 150000, China
Hunan Cancer Hospital
RECRUITING

Changsha, Hunan, China

Contact
MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
NEXT Dallas
RECRUITING

Irving, Texas, 75039, United States
NEXT Virginia
RECRUITING

Fairfax, Virginia, 22031, United States
Peking University Cancer Hospital
RECRUITING

Beijing, Beijing Municipality, 100142, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Renji Hospital Shanghai Jiaotong University School of Medicine
RECRUITING

Shanghai, Shanghai Municipality, China

Contact
Sarah Cannon Research Institute
RECRUITING

Denver, Colorado, 80218, United States
Sarah Cannon Research Institute
RECRUITING

Sarasota, Florida, 34232, United States
Sarah Cannon Research Institute
RECRUITING

Nashville, Tennessee, 37203, United States
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
RECRUITING

Zhejiang, Hangzhou, 310000, China
UCSF
NOT_YET_RECRUITING

San Francisco, California, 94158, United States
ULCA
RECRUITING

Los Angeles, California, 90095, United States
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITING

Wuhan, Hubei, China

Contact
University of Colorado
RECRUITING

Aurora, Colorado, 80010, United States
Zhongshan Hospital Fudan University
RECRUITING

Shanghai, Shanghai Municipality, China

Contact